Low reliability of anti-KIR4.183–120 peptide auto-antibodies in multiple sclerosis patients
Background: Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a g...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2018-06, Vol.24 (7), p.910-918 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 918 |
|---|---|
| container_issue | 7 |
| container_start_page | 910 |
| container_title | Multiple sclerosis |
| container_volume | 24 |
| creator | Marino, Mariapaola Frisullo, Giovanni Di Sante, Gabriele Samengo, Daniela Maria Provenzano, Carlo Mirabella, Massimiliano Pani, Giovambattista Ria, Francesco Bartoccioni, Emanuela |
| description | Background:
Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a group of MS patients, with amino acids 83–120 being the major epitope. Moreover, a strong correlation between anti-KIR4.183–120 and anti-full-length-protein auto-antibodies titer was reported. However, this finding received limited confirmation.
Objective:
Validation of the diagnostic potential of anti-KIR4.183–120 antibodies in 78 MS patients, 64 healthy blood donors, and 42 individuals with other neurological diseases.
Methods:
Analysis of anti-KIR4.183–120 antibodies by enzyme-linked immunosorbent assay (ELISA) using a mouse antiserum we produced as a new ELISA reliability control. Additionally, evaluation of reactivity against 293-T cells transiently transfected with full-length KIR4.1 by flow cytometry.
Results:
We found antibodies to KIR4.183–120 only in 13 out of 78 (16.6%) MS patients; among these, only 2 were positive for anti-full-length KIR4.1 antibodies.
Conclusion:
Employing a new reliability control and a new cytofluorometric assay, we cannot support anti-KIR4.183–120 auto-antibodies as a reliable biomarker in MS. |
| doi_str_mv | 10.1177/1352458517711275 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_sage_</sourceid><recordid>TN_cdi_proquest_miscellaneous_1903165555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458517711275</sage_id><sourcerecordid>1903165555</sourcerecordid><originalsourceid>FETCH-LOGICAL-j235t-62f5275a26f37be436cbcd5cd0aa82803c09f6dd76353b86b60a1c426411a82d3</originalsourceid><addsrcrecordid>eNpdkM1KAzEUhYMoWKt7lwE3blJzk0kyXUrxp1gQRJcyZCYZSUkn4ySDuPMdfEOfxJQKQu_mHDgfl8NB6BzoDECpK-CCFaIU2QMwJQ7QBAqlCJ0reph9jsk2P0YnMa4ppUpxMUGvq_CBB-udrp136ROHFusuOfKwfCpmUPKfr29gFPe2T85YrMcUyBaog3E2YtfhzeiT673FsfF2CNFF3OvkbJfiKTpqtY_27E-n6OX25nlxT1aPd8vF9YqsGReJSNaKXFkz2XJV24LLpm6MaAzVumQl5Q2dt9IYJbngdSlrSTU0BZMFQAYMn6LL3d9-CO-jjanauNhY73VnwxgrmFMOUuTL6MUeug7j0OV2FaOCMyF5KTNFdlTUb_afAFptx672x-a_uO9wHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2053256386</pqid></control><display><type>article</type><title>Low reliability of anti-KIR4.183–120 peptide auto-antibodies in multiple sclerosis patients</title><source>Access via SAGE</source><creator>Marino, Mariapaola ; Frisullo, Giovanni ; Di Sante, Gabriele ; Samengo, Daniela Maria ; Provenzano, Carlo ; Mirabella, Massimiliano ; Pani, Giovambattista ; Ria, Francesco ; Bartoccioni, Emanuela</creator><creatorcontrib>Marino, Mariapaola ; Frisullo, Giovanni ; Di Sante, Gabriele ; Samengo, Daniela Maria ; Provenzano, Carlo ; Mirabella, Massimiliano ; Pani, Giovambattista ; Ria, Francesco ; Bartoccioni, Emanuela</creatorcontrib><description>Background:
Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a group of MS patients, with amino acids 83–120 being the major epitope. Moreover, a strong correlation between anti-KIR4.183–120 and anti-full-length-protein auto-antibodies titer was reported. However, this finding received limited confirmation.
Objective:
Validation of the diagnostic potential of anti-KIR4.183–120 antibodies in 78 MS patients, 64 healthy blood donors, and 42 individuals with other neurological diseases.
Methods:
Analysis of anti-KIR4.183–120 antibodies by enzyme-linked immunosorbent assay (ELISA) using a mouse antiserum we produced as a new ELISA reliability control. Additionally, evaluation of reactivity against 293-T cells transiently transfected with full-length KIR4.1 by flow cytometry.
Results:
We found antibodies to KIR4.183–120 only in 13 out of 78 (16.6%) MS patients; among these, only 2 were positive for anti-full-length KIR4.1 antibodies.
Conclusion:
Employing a new reliability control and a new cytofluorometric assay, we cannot support anti-KIR4.183–120 auto-antibodies as a reliable biomarker in MS.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458517711275</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Autoantibodies ; Biomarkers ; Blood donors ; Enzyme-linked immunosorbent assay ; Epitopes ; Flow cytometry ; Immunoglobulins ; Immunoreactivity ; Lymphocytes T ; Multiple sclerosis ; Neurological diseases ; Potassium channels (inwardly-rectifying)</subject><ispartof>Multiple sclerosis, 2018-06, Vol.24 (7), p.910-918</ispartof><rights>The Author(s), 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458517711275$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458517711275$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids></links><search><creatorcontrib>Marino, Mariapaola</creatorcontrib><creatorcontrib>Frisullo, Giovanni</creatorcontrib><creatorcontrib>Di Sante, Gabriele</creatorcontrib><creatorcontrib>Samengo, Daniela Maria</creatorcontrib><creatorcontrib>Provenzano, Carlo</creatorcontrib><creatorcontrib>Mirabella, Massimiliano</creatorcontrib><creatorcontrib>Pani, Giovambattista</creatorcontrib><creatorcontrib>Ria, Francesco</creatorcontrib><creatorcontrib>Bartoccioni, Emanuela</creatorcontrib><title>Low reliability of anti-KIR4.183–120 peptide auto-antibodies in multiple sclerosis patients</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background:
Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a group of MS patients, with amino acids 83–120 being the major epitope. Moreover, a strong correlation between anti-KIR4.183–120 and anti-full-length-protein auto-antibodies titer was reported. However, this finding received limited confirmation.
Objective:
Validation of the diagnostic potential of anti-KIR4.183–120 antibodies in 78 MS patients, 64 healthy blood donors, and 42 individuals with other neurological diseases.
Methods:
Analysis of anti-KIR4.183–120 antibodies by enzyme-linked immunosorbent assay (ELISA) using a mouse antiserum we produced as a new ELISA reliability control. Additionally, evaluation of reactivity against 293-T cells transiently transfected with full-length KIR4.1 by flow cytometry.
Results:
We found antibodies to KIR4.183–120 only in 13 out of 78 (16.6%) MS patients; among these, only 2 were positive for anti-full-length KIR4.1 antibodies.
Conclusion:
Employing a new reliability control and a new cytofluorometric assay, we cannot support anti-KIR4.183–120 auto-antibodies as a reliable biomarker in MS.</description><subject>Autoantibodies</subject><subject>Biomarkers</subject><subject>Blood donors</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Epitopes</subject><subject>Flow cytometry</subject><subject>Immunoglobulins</subject><subject>Immunoreactivity</subject><subject>Lymphocytes T</subject><subject>Multiple sclerosis</subject><subject>Neurological diseases</subject><subject>Potassium channels (inwardly-rectifying)</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkM1KAzEUhYMoWKt7lwE3blJzk0kyXUrxp1gQRJcyZCYZSUkn4ySDuPMdfEOfxJQKQu_mHDgfl8NB6BzoDECpK-CCFaIU2QMwJQ7QBAqlCJ0reph9jsk2P0YnMa4ppUpxMUGvq_CBB-udrp136ROHFusuOfKwfCpmUPKfr29gFPe2T85YrMcUyBaog3E2YtfhzeiT673FsfF2CNFF3OvkbJfiKTpqtY_27E-n6OX25nlxT1aPd8vF9YqsGReJSNaKXFkz2XJV24LLpm6MaAzVumQl5Q2dt9IYJbngdSlrSTU0BZMFQAYMn6LL3d9-CO-jjanauNhY73VnwxgrmFMOUuTL6MUeug7j0OV2FaOCMyF5KTNFdlTUb_afAFptx672x-a_uO9wHw</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Marino, Mariapaola</creator><creator>Frisullo, Giovanni</creator><creator>Di Sante, Gabriele</creator><creator>Samengo, Daniela Maria</creator><creator>Provenzano, Carlo</creator><creator>Mirabella, Massimiliano</creator><creator>Pani, Giovambattista</creator><creator>Ria, Francesco</creator><creator>Bartoccioni, Emanuela</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20180601</creationdate><title>Low reliability of anti-KIR4.183–120 peptide auto-antibodies in multiple sclerosis patients</title><author>Marino, Mariapaola ; Frisullo, Giovanni ; Di Sante, Gabriele ; Samengo, Daniela Maria ; Provenzano, Carlo ; Mirabella, Massimiliano ; Pani, Giovambattista ; Ria, Francesco ; Bartoccioni, Emanuela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j235t-62f5275a26f37be436cbcd5cd0aa82803c09f6dd76353b86b60a1c426411a82d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Autoantibodies</topic><topic>Biomarkers</topic><topic>Blood donors</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Epitopes</topic><topic>Flow cytometry</topic><topic>Immunoglobulins</topic><topic>Immunoreactivity</topic><topic>Lymphocytes T</topic><topic>Multiple sclerosis</topic><topic>Neurological diseases</topic><topic>Potassium channels (inwardly-rectifying)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marino, Mariapaola</creatorcontrib><creatorcontrib>Frisullo, Giovanni</creatorcontrib><creatorcontrib>Di Sante, Gabriele</creatorcontrib><creatorcontrib>Samengo, Daniela Maria</creatorcontrib><creatorcontrib>Provenzano, Carlo</creatorcontrib><creatorcontrib>Mirabella, Massimiliano</creatorcontrib><creatorcontrib>Pani, Giovambattista</creatorcontrib><creatorcontrib>Ria, Francesco</creatorcontrib><creatorcontrib>Bartoccioni, Emanuela</creatorcontrib><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marino, Mariapaola</au><au>Frisullo, Giovanni</au><au>Di Sante, Gabriele</au><au>Samengo, Daniela Maria</au><au>Provenzano, Carlo</au><au>Mirabella, Massimiliano</au><au>Pani, Giovambattista</au><au>Ria, Francesco</au><au>Bartoccioni, Emanuela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low reliability of anti-KIR4.183–120 peptide auto-antibodies in multiple sclerosis patients</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>24</volume><issue>7</issue><spage>910</spage><epage>918</epage><pages>910-918</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Background:
Multiple sclerosis (MS) is an autoimmune disease for which auto-antibodies fully validated as diagnostic and prognostic biomarkers are widely desired. Recently, an immunoreactivity against the inward rectifying potassium channel 4.1 (KIR4.1) has been reported in a large proportion of a group of MS patients, with amino acids 83–120 being the major epitope. Moreover, a strong correlation between anti-KIR4.183–120 and anti-full-length-protein auto-antibodies titer was reported. However, this finding received limited confirmation.
Objective:
Validation of the diagnostic potential of anti-KIR4.183–120 antibodies in 78 MS patients, 64 healthy blood donors, and 42 individuals with other neurological diseases.
Methods:
Analysis of anti-KIR4.183–120 antibodies by enzyme-linked immunosorbent assay (ELISA) using a mouse antiserum we produced as a new ELISA reliability control. Additionally, evaluation of reactivity against 293-T cells transiently transfected with full-length KIR4.1 by flow cytometry.
Results:
We found antibodies to KIR4.183–120 only in 13 out of 78 (16.6%) MS patients; among these, only 2 were positive for anti-full-length KIR4.1 antibodies.
Conclusion:
Employing a new reliability control and a new cytofluorometric assay, we cannot support anti-KIR4.183–120 auto-antibodies as a reliable biomarker in MS.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.1177/1352458517711275</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2018-06, Vol.24 (7), p.910-918 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1903165555 |
| source | Access via SAGE |
| subjects | Autoantibodies Biomarkers Blood donors Enzyme-linked immunosorbent assay Epitopes Flow cytometry Immunoglobulins Immunoreactivity Lymphocytes T Multiple sclerosis Neurological diseases Potassium channels (inwardly-rectifying) |
| title | Low reliability of anti-KIR4.183–120 peptide auto-antibodies in multiple sclerosis patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T16%3A08%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sage_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20reliability%20of%20anti-KIR4.183%E2%80%93120%20peptide%20auto-antibodies%20in%20multiple%20sclerosis%20patients&rft.jtitle=Multiple%20sclerosis&rft.au=Marino,%20Mariapaola&rft.date=2018-06-01&rft.volume=24&rft.issue=7&rft.spage=910&rft.epage=918&rft.pages=910-918&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458517711275&rft_dat=%3Cproquest_sage_%3E1903165555%3C/proquest_sage_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2053256386&rft_id=info:pmid/&rft_sage_id=10.1177_1352458517711275&rfr_iscdi=true |